WO2023073672 - THERAPEUTIC AND VACCINE CANDIDATES AGAINST SARS-COV-2
National phase entry is expected:
Publication Number
WO/2023/073672
Publication Date
04.05.2023
International Application No.
PCT/IB2022/060499
International Filing Date
31.10.2022
Title **
[English]
THERAPEUTIC AND VACCINE CANDIDATES AGAINST SARS-COV-2
[French]
AGENTS THÉRAPEUTIQUES ET VACCINS CANDIDATS CONTRE SRAS-COV-2
Applicants **
GENEONE LIFE SCIENCE, INC.
Inventors
MUTHUMANI, Kar
Priority Data
63/263,311
29.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2252 | |
| EPO | Filing, Examination, Granting | 12351 | |
| Japan | Filing, Examination, Granting | 2149 | |
| South Korea | Filing, Examination, Granting | 1619 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
23,711
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein is an immunogenic composition comprising a synthetic antigen to COVID spike proteins, particularly the chimeric intermediate structure C-A Complex. Also disclosed herein is a method of preventing and/or treating a COVID infection in a subject in need thereof, by administering the immunogenic composition to the subject.[French]
L'invention concerne une composition immunogène comprenant un antigène synthétique à des protéines spike de la COVID, en particulier la structure intermédiaire chimère du complexe C-A. Une méthode de prévention et/ou de traitement d'une infection par COVID chez un patient en ayant besoin, par administration de la composition immunogène au patient est également divulguée.